Guardian Bio
Biotech startup developing dendritic cell-based therapies to control immunity for cancer treatment.
About
Technology stack
detected 2026-06-18No comments yet. Be the first to share your take.
What does Guardian Bio do?
Guardian Bio is developing a dendritic cell-based platform for cancer therapy, focused on controlling immunity using next-generation cell therapies. Co-founded in 2022 by Ananya Zutshi (BSE Duke, MS/MBA Harvard, Blavatnik Fellow) and Ricky Barrett, the YC-backed company is pioneering novel approaches to immuno-oncology. Guardian Bio has raised $500K from investors including Creative Destruction Lab, Brazen Capital, and Fundament.
How much funding has Guardian Bio raised?
Guardian Bio has raised a total of $500K in funding. The most recent round on record is Pre-Seed.
Where is Guardian Bio headquartered?
Guardian Bio is headquartered in United States.
When was Guardian Bio founded?
Guardian Bio was founded in 2022.
What industry does Guardian Bio operate in?
Guardian Bio operates in AI, Biotech, Immuno-Oncology, Cell Therapy.
How many employees does Guardian Bio have?
Guardian Bio has approximately 5 people on record.